secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0000950170-23-009852
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics reports Q4 2022 net loss $29.1M; TNG462 gets Fast Track; appoints new R&D President
--------------------------------------------------------------------------------

- Net loss of $29.1M in Q4 2022 ($0.33/share) vs $22.0M ($0.25) in Q4 2021; FY2022 net loss $108.2M ($1.23) vs $58.2M ($0.94).
- Cash of $366.1M at Dec 31, 2022 expected to fund operations into 2025.
- FDA granted Fast Track Designation to TNG462, a next-gen MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers.
- Adam Crystal, M.D., Ph.D. appointed President of Research and Development in February 2023.
- Upcoming: TNG908 proof-of-mechanism update Q2 2023; IND filings for TNG260 (H1 2023) and TNG348 (mid-2023).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017023009852/0000950170-23-009852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017023009852/tngx-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer